Literature DB >> 25692218

Synchrony in serum antibody response to conserved proteins of Streptococcus pneumoniae in young children.

Dabin Ren1, Anthony L Almudevar, Michael E Pichichero.   

Abstract

Conserved Streptococcus pneumoniae (Spn) proteins are currently under investigation as vaccine candidates. We recently identified a subset of children prone to frequent acute otitis media (AOM) that we refer to as stringently-defined otitis prone (sOP). We investigated the synchrony of serum antibody responses against 5 Spn protein vaccine antigens, PhtD, LytB, PcpA, PhtE, and PlyD1 resulting from nasopharyngeal colonization and AOM in sOP children (49 observations) and non-otitis prone (NOP) children (771 observations). Changes in serum IgG and IgM were quantitated with ELISA. IgG antibody concentrations against PhtD, PcpA, and PlyD1 rose in synchrony in sOP and NOP children; that is, the proteins appeared equally and highly immunogenic in children at age 6 to 15 months and then leveled off in their rise at 15 to 25 months. In contrast, rises in concentrations to PhtE and LytB were significantly slower and had not peaked in children even at 25 months of age, consistent with lower immunogenicity. Serum IgM responses against PhtD and PlyD1 were in synchrony in children at age 6-25 months old. PcpA did not induce a significant increase of serum IgM response in children, suggesting that primary responses to PcpA occurred prior to children attaining age 6 months old. PhtD, PcpA, and Ply elicit a synchronous natural acquisition of serum antibody in young children suggesting that a trivalent Spn protein vaccine combining PhtD, PcpA, and PlyD1 would be less likely to display antigen competition when administered as a combination vaccine in young children.

Entities:  

Keywords:  AOM, acute otitis media; ELISA, Enzyme-linked Immunosorbent Assay; GAM, generalized additive model; GAMM, generalized additive mixed model; LC, log10 Concentration; LME, linear mixed effects; NOP, non-otitis prone; NP, nasopharyngeal; OP, otitis prone; PCV, pneumococcal conjugate vaccine; PcpA, pneumococcal choline binding protein A; PhtD, pneumococcal histidine triad protein D; PhtE, pneumococcal histidine triad protein E; Ply, pneumolysin; PlyD1, pneumolysin derivative 1; Spn, Streptococcus pneumoniae; Streptococcus pneumoniae; generalized additive mixed model; generalized additive model; nasopharynx; pneumococcal choline binding protein A; pneumococcal conjugate vaccine; pneumococcal histidine triad protein D; pneumococcal histidine triad protein E; pneumolysin; sOP, stringently-defined otitis prone

Mesh:

Substances:

Year:  2015        PMID: 25692218      PMCID: PMC4514345          DOI: 10.4161/21645515.2014.990861

Source DB:  PubMed          Journal:  Hum Vaccin Immunother        ISSN: 2164-5515            Impact factor:   3.452


  41 in total

1.  Pneumococcal carriage and otitis media induce salivary antibodies to pneumococcal surface adhesin a, pneumolysin, and pneumococcal surface protein a in children.

Authors:  B Simell; M Korkeila; H Pursiainen; T M Kilpi; H Käyhty
Journal:  J Infect Dis       Date:  2001-02-21       Impact factor: 5.226

Review 2.  Aluminium compounds as adjuvants for vaccines and toxoids in man: a review.

Authors:  M A Aprile; A C Wardlaw
Journal:  Can J Public Health       Date:  1966-08

3.  Do antibodies to pneumococcal surface adhesin a prevent pneumococcal involvement in acute otitis media?

Authors:  S Rapola; T Kilpi; M Lahdenkari; A K Takala; P H Mäkelä; H Käyhty
Journal:  J Infect Dis       Date:  2001-07-30       Impact factor: 5.226

Review 4.  Molecular pathogenesis of pneumococcal pneumonia.

Authors:  J A McCullers; E I Tuomanen
Journal:  Front Biosci       Date:  2001-08-01

5.  Natural materno-fetal transfer of antibodies to PspA and to PsaA.

Authors:  L Baril; D E Briles; P Crozier; J D King; S K Hollingshead; T F Murphy; J B McCormick
Journal:  Clin Exp Immunol       Date:  2004-03       Impact factor: 4.330

6.  Immunizations with pneumococcal surface protein A and pneumolysin are protective against pneumonia in a murine model of pulmonary infection with Streptococcus pneumoniae.

Authors:  David E Briles; Susan K Hollingshead; James C Paton; Edwin W Ades; Lea Novak; Frederik W van Ginkel; William H Benjamin
Journal:  J Infect Dis       Date:  2003-07-14       Impact factor: 5.226

7.  Emergence of a multiresistant serotype 19A pneumococcal strain not included in the 7-valent conjugate vaccine as an otopathogen in children.

Authors:  Michael E Pichichero; Janet R Casey
Journal:  JAMA       Date:  2007-10-17       Impact factor: 56.272

8.  What is the natural history of recurrent acute otitis media in infancy?

Authors:  O P Alho; E Läärä; H Oja
Journal:  J Fam Pract       Date:  1996-09       Impact factor: 0.493

9.  Streptococcus pneumoniae surface protein PcpA elicits protection against lung infection and fatal sepsis.

Authors:  David T Glover; Susan K Hollingshead; David E Briles
Journal:  Infect Immun       Date:  2008-04-07       Impact factor: 3.441

10.  Large-scale identification of serotype 4 Streptococcus pneumoniae virulence factors.

Authors:  David L Hava; Andrew Camilli
Journal:  Mol Microbiol       Date:  2002-09       Impact factor: 3.501

View more
  7 in total

Review 1.  Pneumococcal whole-cell and protein-based vaccines: changing the paradigm.

Authors:  Michael E Pichichero
Journal:  Expert Rev Vaccines       Date:  2017-12       Impact factor: 5.217

2.  Serum antibody response to Moraxella catarrhalis proteins in stringently defined otitis prone children.

Authors:  Dabin Ren; Anthony L Almudevar; Timothy F Murphy; Eric R Lafontaine; Anthony A Campagnari; Nicole Luke-Marshall; Michael E Pichichero
Journal:  Vaccine       Date:  2017-07-26       Impact factor: 3.641

3.  Natural Development of Antibodies against Streptococcus pneumoniae, Haemophilus influenzae, and Moraxella catarrhalis Protein Antigens during the First 13 Years of Life.

Authors:  Igor C Borges; Dafne C Andrade; Maria Regina A Cardoso; Jorma Toppari; Mari Vähä-Mäkilä; Jorma Ilonen; Mikael Knip; Heikki Hyöty; Riitta Veijola; Olli Simell; Tuomas Jartti; Helena Käyhty; Olli Ruuskanen; Cristiana M Nascimento-Carvalho
Journal:  Clin Vaccine Immunol       Date:  2016-11-04

Review 4.  Panel 6: Vaccines.

Authors:  Melinda M Pettigrew; Mark R Alderson; Lauren O Bakaletz; Stephen J Barenkamp; Anders P Hakansson; Kevin M Mason; Johanna Nokso-Koivisto; Janak Patel; Stephen I Pelton; Timothy F Murphy
Journal:  Otolaryngol Head Neck Surg       Date:  2017-04       Impact factor: 3.497

5.  A Cross-Reactive Protein Vaccine Combined with PCV-13 Prevents Streptococcus pneumoniae- and Haemophilus influenzae-Mediated Acute Otitis Media.

Authors:  Hannah M Rowe; Beth Mann; Amy Iverson; Aaron Poole; Elaine Tuomanen; Jason W Rosch
Journal:  Infect Immun       Date:  2019-09-19       Impact factor: 3.441

6.  Modeling specific antibody responses to natural immunization to predict a correlate of protection against infection before commencing a clinical vaccine trial.

Authors:  Anthony Almudevar; Michael E Pichichero
Journal:  Hum Vaccin Immunother       Date:  2017-10-03       Impact factor: 3.452

Review 7.  Next generation protein based Streptococcus pneumoniae vaccines.

Authors:  Michael E Pichichero; M Nadeem Khan; Qingfu Xu
Journal:  Hum Vaccin Immunother       Date:  2016       Impact factor: 3.452

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.